Revenue Growth - Revenue increased 70% to $501,000 in Q4 2024 compared to $295,000 in Q4 2023, driven by a 206% growth in e-commerce[4] - The Evolve™ Rat product contributed approximately 52% of Q4 2024 revenue, while the Evolve™ Mouse contributed 24%[4] Profitability - Gross profit margin improved to 60.9% in Q4 2024 from 43.7% in Q4 2023[4] - Adjusted EBITDA loss for Q4 2024 was $1.1 million, compared to $1.6 million in Q4 2023, marking the smallest quarterly loss in company history[4][7] Operating Expenses - Operating expenses decreased by 16% in Q4 2024 compared to Q4 2023[4] - The company plans to reduce expenses by approximately $2 million annually through new operating optimization initiatives[6] Net Loss - Net loss for Q4 2024 was $1.3 million, an improvement from a net loss of $1.7 million in Q4 2023[4] Cash Flow Breakeven - The revenue threshold for cash flow breakeven is expected to decrease to approximately $7 million annually, down from $12 million[6] Distribution and Packaging - The company has signed agreements for distribution of Evolve in 10 countries, with product shipments already occurring in Hong Kong, UAE, Netherlands, and Maldives[9] - The company launched new packaging options that use 87% less plastic than traditional pails, enhancing gross margins[9]

Core Viewpoint - SenesTech, Inc. has reported significant financial improvements in Q4 2024, including a 70% increase in revenue and a strategic focus on operating optimization initiatives aimed at reducing expenses by approximately $2 million annually to accelerate profitability [1][7][6]. Financial Performance - Revenue for Q4 2024 increased by 70% to $501,000 compared to $295,000 in Q4 2023, driven by a 206% growth in e-commerce [5]. - Gross profit margin improved to 60.9% in Q4 2024 from 43.7% in Q4 2023 [5]. - Operating expenses decreased by 16% in Q4 2024 compared to the same quarter in 2023 [5]. - Net loss for Q4 2024 was $1.3 million, an improvement from a net loss of $1.7 million in Q4 2023 [5]. - Adjusted EBITDA loss for Q4 2024 was $1.1 million, down from $1.6 million in Q4 2023 [5]. Key Growth Initiatives - The Evolve™ Rat product line became the largest revenue contributor, accounting for approximately 52% of Q4 2024 revenue [5]. - The Evolve™ Mouse product, launched in May 2024, contributed 24% of Q4 2024 revenue [5]. - The company has expanded its distribution through major online retailers, including Amazon and Walmart [5]. - Municipal programs for rodent contraception have been initiated in cities like New York, Baltimore, Chicago, and Boston [5]. - International distribution agreements have been signed in 10 countries, with product shipments already occurring in several regions [5]. Operating Optimization Initiatives - New initiatives are expected to reduce expenses by $2 million annually, lowering the revenue threshold for cash flow breakeven to approximately $7 million from a previous estimate of $12 million [6][8]. - The company aims to enhance operational efficiencies and streamline costs to accelerate its path to profitability [6][8]. Management Commentary - The CEO highlighted the transformational year for SenesTech, emphasizing strong financial results and the smallest quarterly Adjusted EBITDA loss in the company's history [7]. - The management is committed to a focused strategy that targets sustainable long-term success in the multi-billion-dollar rodent control market [8].

Core Viewpoint - SenesTech, Inc. has entered into definitive agreements for the immediate exercise of certain outstanding warrants, allowing the purchase of 374,718 shares at a reduced exercise price, aiming to raise capital for working and corporate purposes [1][3]. Group 1: Warrant Exercise and Financial Details - The existing warrants, originally priced at $4.35 per share, will now be exercised at $2.90 per share, generating approximately $1.1 million in gross proceeds before fees [1][3]. - New short-term warrants will be issued, potentially raising an additional $4.3 million if fully exercised [3][5]. - The new short-term warrants will allow the purchase of up to 1,498,872 shares at the same reduced price of $2.90 per share [5]. Group 2: Regulatory and Compliance Information - The resale of shares from the existing warrants has been registered under an effective registration statement [4]. - The new short-term warrants have not been registered under the Securities Act of 1933, meaning they cannot be sold in the U.S. without proper registration or exemption [6]. Group 3: Company Overview - SenesTech focuses on humane pest management solutions, particularly through its Evolve™ rodent birth control product, aiming to create healthier environments and reduce reliance on traditional poisons [8].

Core Viewpoint - SenesTech, Inc. will release its financial results for the fourth quarter and fiscal year 2024 on March 12, 2025, after market close, followed by a conference call to discuss the results [1]. Group 1: Financial Results Announcement - The financial results for the fourth quarter and fiscal year 2024 will be reported after market close on March 12, 2025 [1]. - A conference call is scheduled for the same day at 5:00 pm ET to review the financial results [1]. Group 2: Conference Call Details - Interested parties can join the conference call by dialing (844) 308-3351 or (412) 317-5407 [2]. - A live webcast of the conference call will be available on the Investor Relations section of the company's website [2]. Group 3: Replay Information - A teleconference replay will be available for seven days at (877) 344-7529 or (412) 317-0088, with a replay access code of 7759112 [3]. - A webcast replay will be accessible for 90 days in the Investor Relations section of the company's website [3]. Group 4: Company Overview - SenesTech is focused on humane management of animal pest populations through fertility control, aiming to create healthier environments [4]. - The company's products, such as Evolve™ rodent birth control, enhance pest management effectiveness while reducing reliance on traditional poisons [4].

Core Insights - SenesTech is expanding its rodent fertility control solutions, Evolve™ Rat and Evolve™ Mouse, into New Zealand and Australia through a partnership with Evicom, targeting the Predator Free 2050 initiative in New Zealand [1][4] - The company anticipates regulatory approval for Evolve in New Zealand by Q3 2025, with shipments expected to start in late Q2 or early Q3 2025 [2] - Evolve offers a sustainable and humane alternative to traditional rodenticides, addressing ecological and economic challenges posed by rodent overpopulation [3][6] Market Opportunities - New Zealand's Predator Free 2050 initiative aims to eradicate invasive predators, with an expected investment of over $4.5 billion, making Evolve a fitting solution for this conservation effort [4] - Australia spends approximately $100 million annually on rodent pest control, with a growth rate exceeding 5% per year, indicating a rising demand for sustainable pest management solutions [5] - SenesTech projects that regional annual demand for Evolve could rapidly reach or exceed $500,000, bolstered by Evicom's partnerships in government and private sectors [6]

PHOENIX, Feb. 10, 2025 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES, "SenesTech"), a pioneer in humane rodent pest control solutions, is pleased to announce that its Evolve™ Rodent Birth Control product line is now available for purchase on TractorSupply.com. This expansion represents another key milestone in SenesTech's e-commerce growth strategy, bringing its innovative and effective rodent control solution to a broader customer base nationwide.Tractor Supply Company is the largest rural lifestyle retail ...

PHOENIX, Feb. 4, 2025 /PRNewswire/ -- SenesTech, Inc. (Nasdaq: SNES), a pioneer in humane pest control solutions, is pleased to announce its plans to enter the Indian rodent pest control market through a partnership with SMark, a well-established distributor based in India. The partnership is cemented by a recently signed letter of intent, underscoring the shared commitment to bringing innovative, non-lethal rodent control solutions to this rapidly growing market.India presents a significant opportunity for ...

Core Insights - SenesTech, Inc. has announced the integration of its rodent birth control product, Evolve™, into Baltimore's rodent management programs, marking a significant step in addressing the city's rodent population issue [1][5] - Evolve™ offers a humane and sustainable solution by targeting rodent reproduction, thereby reducing populations over time without lethal methods [2][4] Company Overview - SenesTech is focused on creating healthier environments through humane pest management solutions, emphasizing fertility control as a means to manage animal pest populations [6] - The company's mission includes enhancing pest management effectiveness while reducing reliance on traditional poisons, aiming for cleaner cities and healthier communities [6] Product Details - Evolve™ is designed to restrict reproduction in both male and female rodents, providing a non-lethal approach to pest control that complements traditional methods [2][4] - The product has received an EPA-designated "minimum risk" classification, ensuring safety for people, pets, wildlife, and the environment [4] Implementation in Baltimore - The City of Baltimore has placed a substantial initial order for Evolve™ and plans to deploy it in high-impact areas as part of its integrated pest management strategy [1][5] - The initiative aims to evaluate the effectiveness of Evolve™ in reducing rodent populations while minimizing environmental and public health risks [5]

Company Overview - SenesTech is a pioneer in humane pest control solutions, specializing in fertility control technologies to manage animal pest populations [8] - The company has developed innovative products like ContraPest®, the only EPA-registered contraceptive for both male and female rats, and Evolve™, an EPA-designated minimum-risk contraceptive soft bait [8] - SenesTech aims to create healthier environments by reducing reliance on traditional poisons and integrating its products seamlessly into pest management programs [8] Product Launch and Distribution - Evolve™ Rodent Birth Control, an innovative rodent control product, will soon be available through Bug Off Pest Control in New York City [1] - Bug Off will market and sell Evolve throughout its network and provide ongoing training to pest management professionals (PMPs) in the Greater New York area [1] - The partnership with Bug Off is expected to accelerate market penetration in New York City, a key and challenging market for rodent control [2][3] Product Features and Effectiveness - Evolve is a soft bait that is highly palatable to rodents, making it easy to deploy in various environments such as barns, garages, homes, gardens, and sheds [4][10] - The product works by reducing rodent fertility, addressing the root cause of overpopulation and providing long-lasting results [10] - Evolve has been tested and proven effective in reducing rodent populations without the use of traditional poisons [4] Market Context - New York City is implementing a rat contraception program, and SenesTech is currently the only manufacturer of products that meet the EPA's requirements for rat contraceptives [7] - The city's program defines "rat contraceptive" as an agent approved by the EPA for reducing reproductive capacity in rats, aligning with SenesTech's product offerings [7] Strategic Partnerships - Bug Off and its President, Andy Linares, are well-respected in the pest management industry, known for their focus on innovation, education, and service [2] - The collaboration with Bug Off is expected to enhance the adoption of Evolve in New York City, leveraging Bug Off's reputation and network [2][3]

Company Announcement - SenesTech, Inc announces Joshua M Moss will join its Board of Directors [1] - Joshua M Moss is co-founder, Managing Director and Portfolio Manager at EAM Global Investors, a boutique investment firm with approximately $3 billion in assets under management [2] - He has over 20 years of experience in institutional investment management, with a proven track record in portfolio management, team leadership and global business development [2] - Previously held senior roles at Allianz Global Investors and began his career at Credit Suisse focusing on investment banking and equity research [3] - Holds an MBA in Finance from UCLA Anderson School of Management and a BA in History from University of California, San Diego [4] Business Outlook - SenesTech and its product Evolve are poised for growth in the coming year and beyond according to Mr Moss [5] - The company has the right team and product to drive this growth [5] Company Overview - SenesTech is committed to creating healthier environments through humane animal pest population management using fertility control [6] - The company is an expert in fertility control technologies and has pioneered products like ContraPest and Evolve [6] - ContraPest is the only EPA-registered contraceptive for both male and female rats [6] - Evolve is an EPA-designated minimum-risk contraceptive soft bait [6] - Both products are designed to integrate seamlessly into pest management programs, enhancing effectiveness while reducing reliance on traditional poisons [6] - The company aims to create cleaner cities, more efficient businesses and happier households with humane, effective and sustainable products [6]